News

Sarepta halts Elevidys shipments following FDA pressure
Sarepta CEO Doug Ingram said it is important the company maintains a “positive working relationship” with the FDA.
Sarepta Stock Is Falling. How Its Crisis Went From Bad to Worse.
Most investors don’t see the drugmaker’s executive management as credible, following the failure to disclose a patient death, ...
The Pharma Letter1h
Sarepta agrees to ‘painful’ pause of Elevidys shipments
Shares in Sarepta Therapeutics have slumped by more than a third since late last week amid new updates on its gene therapy ...
pharmaphorum2h
Sarepta backs down and pauses Elevidys shipments
The FDA appears to have won its staring contest with Sarepta over shipments of Elevidys, after the company blinked and agreed ...
GEN - Genetic Engineering and Biotechnology News9h
About Face: Sarepta to Pause Elevidys Shipments Temporarily
Sarepta Therapeutics said it will voluntarily “and temporarily” pause all shipments of Elevidys® (delandistrogene ...
Fierce Biotech3d
UPDATED: Analysts demand transparency after Sarepta's roundabout disclosure of 3rd patient death
On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.
Sarepta's Shocking Stand: Company Rejects FDA Request To Pull Gene Therapy Elevidys
FDA places clinical hold on Sarepta's LGMD gene therapy trials after three deaths and revokes platform tech designation due ...
Sarepta Therapeutics stock sinks after FDA tells company to stop shipping its bestselling drug
Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an ...